Supplementary Materials

Supplementary Material for:

Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin

Ashley M. Laughney, Eunha Kim, Melissa M. Sprachman, Miles A. Miller, Rainer H. Kohler, Katy S. Yang, James D. Orth, Timothy J. Mitchison, Ralph Weissleder*

*Corresponding author. E-mail: rweissleder{at}mgh.harvard.edu

Published 5 November 2014, Sci. Transl. Med. 6, 261ra152 (2014)
DOI: 10.1126/scitranslmed.3009318

This PDF file includes:

  • Methods
  • Fig. S1. Chemistry of eribulin-BODIPY (BFL).
  • Fig. S2. 1H NMR spectrum of eribulin-BFL.
  • Fig. S3. Microtubule disassembly in HT1080 cells with variable drug accumulation.
  • Fig. S4. Eribulin-BFL is a substrate of MDR1; BODIPY fluorophore (BFL) alone is not.
  • Fig. S5. Characterization of the MDR1-mApple fusion protein cell line.
  • Fig. S6. Relevance of MRP7 to resistance cancer model and eribulin-BFL PK.
  • Fig. S7. Comparison of unlabeled and labeled eribulin cytotoxicity profiles.
  • Fig. S8. Half-life of eribulin-BFL in vivo.
  • Fig. S9. Modeling of eribulin-BFL cellular PK in wild-type and resistant human cancer cells.
  • Fig. S10. Evaluation of potential MDR1 inhibitors in wild-type and resistant cells.
  • Fig. S11. Toxicity profile of the nanoencapsulated MDR1 inhibitor in vitro.

[Download PDF]